$EYPT
EyePoint Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123267 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $10.52M
YoY Change -30.77%
Cost Of Revenue $736.0K
YoY Change -38.67%
Gross Profit $9.788M
YoY Change -30.09%
Gross Profit Margin 93.01%
Selling, General & Admin $12.99M
YoY Change 17.75%
% of Gross Profit 132.75%
Research & Development $29.54M
YoY Change 70.14%
% of Gross Profit 301.82%
Depreciation & Amortization $408.0K
YoY Change 270.91%
% of Gross Profit 4.17%
Operating Expenses $42.54M
YoY Change 43.7%
Operating Profit -$32.75M
YoY Change 127.45%
Interest Expense $3.387M
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.387M
YoY Change 89.64%
Pretax Income -$29.36M
YoY Change 132.84%
Income Tax
% Of Pretax Income
Net Earnings -$29.36M
YoY Change 132.8%
Net Earnings / Revenue -278.99%
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$0.54
COMMON SHARES
Basic Shares Outstanding 68.25M 53.52M
Diluted Shares Outstanding 54.45M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $253.8M
YoY Change 86.61%
Cash & Equivalents $79.83M
Short-Term Investments $174.0M
Other Short-Term Assets $1.298M
YoY Change 136.43%
Inventory $2.807M
Prepaid Expenses $2.441M
Receivables $378.0K
Other Receivables $0.00
Total Short-Term Assets $268.5M
YoY Change 78.84%
LONG-TERM ASSETS
Property, Plant & Equipment $8.391M
YoY Change 87.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.422M
YoY Change 1111.0%
Total Long-Term Assets $32.37M
YoY Change 227.61%
TOTAL ASSETS
Total Short-Term Assets $268.5M
Total Long-Term Assets $32.37M
Total Assets $300.9M
YoY Change 88.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.343M
YoY Change -23.35%
Accrued Expenses $14.17M
YoY Change 5.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.79M
YoY Change -23.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $233.0K
YoY Change
Total Long-Term Liabilities $233.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $48.79M
Total Long-Term Liabilities $233.0K
Total Liabilities $82.18M
YoY Change -18.97%
SHAREHOLDERS EQUITY
Retained Earnings -$831.6M
YoY Change 14.23%
Common Stock $1.049B
YoY Change 33.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.7M
YoY Change
Total Liabilities & Shareholders Equity $300.9M
YoY Change 88.02%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$29.36M
YoY Change 132.8%
Depreciation, Depletion And Amortization $408.0K
YoY Change 270.91%
Cash From Operating Activities -$39.03M
YoY Change 156.59%
INVESTING ACTIVITIES
Capital Expenditures $1.574M
YoY Change -8.49%
Acquisitions
YoY Change
Other Investing Activities $17.77M
YoY Change
Cash From Investing Activities $16.20M
YoY Change -1041.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.89M
YoY Change 14.8%
NET CHANGE
Cash From Operating Activities -39.03M
Cash From Investing Activities 16.20M
Cash From Financing Activities 11.89M
Net Change In Cash -10.94M
YoY Change 66.5%
FREE CASH FLOW
Cash From Operating Activities -$39.03M
Capital Expenditures $1.574M
Free Cash Flow -$40.60M
YoY Change 139.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51122
dei Entity Registrant Name
EntityRegistrantName
EyePoint Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2774444
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Pleasant Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
926-5000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
EYPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68251031
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79830000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
281263000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
173963000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49787000
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
378000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
805000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11571000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9039000
CY2024Q3 us-gaap Inventory Net
InventoryNet
2807000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3906000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
268549000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
344800000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8391000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5251000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21405000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4983000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2422000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2024Q3 us-gaap Assets
Assets
300917000
CY2023Q4 us-gaap Assets
Assets
355184000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7343000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6504000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14166000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17521000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25996000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
38592000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1289000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
646000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48794000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63263000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11234000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
20692000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21922000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4906000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
233000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2024Q3 us-gaap Liabilities
Liabilities
82183000
CY2023Q4 us-gaap Liabilities
Liabilities
88861000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53524364
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53524364
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49043074
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49043074
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
53000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1049127000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1007556000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-831617000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-742146000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1171000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
864000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
218734000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
266323000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300917000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355184000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10524000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15202000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31685000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31990000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
736000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1202000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2896000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3634000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29542000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17363000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89554000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46711000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
479000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
80000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11504000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12970000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39770000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28854000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
43272000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
29600000
us-gaap Costs And Expenses
CostsAndExpenses
132300000
us-gaap Costs And Expenses
CostsAndExpenses
90703000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32748000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14398000
us-gaap Operating Income Loss
OperatingIncomeLoss
-100615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58713000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3387000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1786000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
11144000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4611000
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1247000
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1347000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3387000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1786000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11144000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2017000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29361000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12612000
us-gaap Net Income Loss
NetIncomeLoss
-89471000
us-gaap Net Income Loss
NetIncomeLoss
-56696000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.5
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54449000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54449000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38341000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38341000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53526000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53526000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37804000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37804000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29361000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12612000
us-gaap Net Income Loss
NetIncomeLoss
-89471000
us-gaap Net Income Loss
NetIncomeLoss
-56696000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
379000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
307000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
55000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28982000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12613000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89164000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56641000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57262000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12612000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9540000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
174000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3629000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
58621000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
228305000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29361000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
379000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11793000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
202000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-78000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7446000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
218734000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
96368000
us-gaap Net Income Loss
NetIncomeLoss
-56696000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9540000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
422000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
634000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-169000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8467000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
58621000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
266323000
us-gaap Net Income Loss
NetIncomeLoss
-89471000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
307000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11811000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
470000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4966000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-4512000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28840000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
218734000
us-gaap Profit Loss
ProfitLoss
-89471000
us-gaap Profit Loss
ProfitLoss
-56696000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1073000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
352000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-4143000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-334000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
693000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1347000
us-gaap Share Based Compensation
ShareBasedCompensation
28840000
us-gaap Share Based Compensation
ShareBasedCompensation
8467000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
2107000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-14701000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2422000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1098000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2224000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2402000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
791000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
1211000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
467000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-22054000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
57420000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90377000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24984000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234225000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5851000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
114500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
52284000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3668000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2600000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-123393000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43833000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11793000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9974000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
307000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
415000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
30000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1350000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5300000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15775000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4512000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
169000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5436000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1056000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
73000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
36000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12337000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31415000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-201433000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37402000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
281413000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95783000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79980000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133185000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79830000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133035000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
150000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
150000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79980000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133185000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
1405000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17544000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
eypt Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
0
eypt Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
19000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="font-size:0;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operations</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, the Company), as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (U.S.) generally accepted accounting principles requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the entire 2024 fiscal year or any future period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s pipeline leverages its proprietary bioerodible Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology (Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, f/k/a EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and a Phase 2 clinical trial for diabetic macular edema (DME). The Company is also advancing EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to potentially improve outcomes in serious retinal diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to identify and advance additional product candidates through clinical and regulatory development for its pipeline. This may be accomplished through internal discovery efforts, research collaborations and/or in-licensing arrangements and potential acquisitions of additional products, product candidates or technologies.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company had cash, cash equivalents and investments in marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">253.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at September 30, 2024. The Company has a history of operating losses and has not had significant recurring cash inflows from revenue. The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income, and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates, and the Company does not expect revenues to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents and investments in marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">253.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at September 30, 2024 will enable the Company to fund its current and planned operations for at least the next twelve months from the date these condensed consolidated financial statements were issued. Actual cash requirements could differ from management’s projections due to many factors, including the timing and results of the Company’s clinical trials for DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, additional investments in research and development programs, competing technological and market developments and the costs of any strategic acquisitions and/or development of compleme</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntary business opportunities.</span></p>
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
253800000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
253800000
CY2023Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
760000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
70000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-551000
CY2024Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
279000
CY2022Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1888000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
1561000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
-169000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-2538000
CY2023Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
742000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2441000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1695000
CY2024Q3 eypt Prepaid Clinical Current
PrepaidClinicalCurrent
7832000
CY2023Q4 eypt Prepaid Clinical Current
PrepaidClinicalCurrent
6335000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1298000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1009000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11571000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9039000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1496000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1303000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
649000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
882000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
662000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1721000
CY2024Q3 us-gaap Inventory Net
InventoryNet
2807000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3906000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8910000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12631000
CY2024Q3 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
3861000
CY2023Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
3305000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
682000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
666000
CY2024Q3 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
279000
CY2023Q4 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
760000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
434000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14166000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17521000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y4M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.116
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1188000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
563000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21922000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4906000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23110000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5469000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
60000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
47000
us-gaap Variable Lease Cost
VariableLeaseCost
195000
us-gaap Variable Lease Cost
VariableLeaseCost
106000
CY2024Q3 us-gaap Lease Cost
LeaseCost
1090000
CY2023Q3 us-gaap Lease Cost
LeaseCost
403000
us-gaap Lease Cost
LeaseCost
2164000
us-gaap Lease Cost
LeaseCost
1173000
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
630000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3585000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4133000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4222000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3319000
CY2024Q3 eypt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
31860000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
47749000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24639000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23110000
CY2021Q4 eypt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
3272727
CY2024Q2 eypt Stock Issued During Period Shares Cashless Exercise Of Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
2181818
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2180776
CY2024Q3 eypt Pre Funded Warrants Outstandings
PreFundedWarrantsOutstandings
1090909
eypt Pre Funded Warrants Shares Included In Net Income Loss Per Share Calculation
PreFundedWarrantsSharesIncludedInNetIncomeLossPerShareCalculation
1090909
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7446000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3629000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28840000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8467000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
64600000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
270500000
CY2024Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
4900000
CY2024Q3 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
4900000
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
5000000
CY2023Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
5000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9048927
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7731609
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 eypt Rule10 B51 Arrangement Modified Flag
Rule10B51ArrangementModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123267-index-headers.html Edgar Link pending
0000950170-24-123267-index.html Edgar Link pending
0000950170-24-123267.txt Edgar Link pending
0000950170-24-123267-xbrl.zip Edgar Link pending
eypt-20240930.htm Edgar Link pending
eypt-20240930.xsd Edgar Link pending
eypt-ex10_1.htm Edgar Link pending
eypt-ex10_2.htm Edgar Link pending
eypt-ex31_1.htm Edgar Link pending
eypt-ex31_2.htm Edgar Link pending
eypt-ex32_1.htm Edgar Link pending
eypt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eypt-20240930_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending